Human Genome Sciences Inc. / Healthcare Funds / Healthcare Trader 1 / Hedge Fund / Investment Bank / /
Continent
Europe / /
Country
France / Cayman Islands / United States / /
Currency
USD / /
Event
M&A / FDA Phase / Person Communication and Meetings / Judicial Event / /
IndustryTerm
treatment of hepatitis C / healthcare / biopharmaceutical / investment bank / /
MedicalCondition
then-leading hepatitis C / hepatitis / liver disease Hepatitis C / diseases / hepatitis C. HGSI / interstitial lung disease / /
NaturalFeature
Cayman Island / /
Organization
Achieve Trial’s Steering Committee / Achieve Trial’s Data Monitoring Committee / NEW YORK SECURITIES AND EXCHANGE COMMISSION / Data Monitoring Committee / American Association for the Study of Liver Diseases / Steering Committee / /
Person
YVES M. BENHAMOU / /
Position
executive officer / Chief of Department / advisor / manager of this fund / portfolio manager / U.S. Investment Advisors / Manager / manager in violation / Investment Advisor / country lead investigator / Co-Portfolio Manager / consultant / investment advisors / Director of an investment bank / a Managing / clinical investigative physician / investment advisors and a co-portfolio manager / co-portfolio manager of six healthcare-related hedge funds / executive officer of Investment / trader / Healthcare Fund Advisors / Professor of Hepatology / CoPortfolio Manager / Associate Professor / /
Product
Pegasys / Albuferon / /
ProvinceOrState
Maryland / New York / Connecticut / Delaware / Massachusetts / /
SEC Complaint: Dr. Yves M. Benhamou